Alliance A022102: Randomized phase III trial of mFOLFIRINOX plus /- nivolumab vs. FOLFOX plus /- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)

被引：0
|
作者：
Park, Haeseong
Geyer, Susan Michelle
Klute, Kelsey
Bleeker, Jonathan
King, Daniel
Strickland, Matthew
Goodrich, Austin
Carlisle, Destin
Shergill, Ardaman
O'Reilly, Eileen Mary
Meyerhardt, Jeffrey A.
Shah, Manish A.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Univ Nebraska Med Ctr, Omaha, NE USA
[5] Sanford Hlth, Sioux Falls, SD USA
[6] Northwell Hlth, New Hyde Pk, NY USA
[7] Massachusetts Gen Hosp, Boston, MA USA
[8] Univ Chicago, Alliance Protocol Operat Off, Chicago, IL USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4175
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer
    He, Kewen
    Wang, Xinzhao
    Guan, Xiyun
    Yu, Qian
    Ma, Qinghua
    Liu, Zhaoyun
    Yu, Zhiyong
    ANTICANCER RESEARCH, 2017, 37 (10) : 5647 - 5653
  • [42] Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
    Al-Batran, Salah-Eddin
    Pauligk, Claudia
    Goetze, Thorsten Oliver
    Riera-Knorrenschild, Jorge
    Goekkurt, Eray
    Angermeier, Stefan
    Kullmann, Frank
    Thuss-Patience, Peter C.
    Homann, Nils
    Ettrich, Thomas Jens
    Junge, Sabine
    Hofheinz, Ralf
    Lorenzen, Sylvie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.
    Shimozaki, Keitaro
    Fukuda, Koshiro
    Ooki, Akira
    Nakayama, Izuma
    Yoshino, Koichiro
    Udagawa, Shohei
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 341 - 341
  • [44] Phase (Ph) II study of zanidatamab plus chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
    Ku, G.
    Elimova, E.
    Denlinger, C. S.
    Mehta, R.
    Lee, K-W.
    Iqbal, S.
    Kang, Y-K.
    Oh, D-Y.
    Rha, S. Y.
    Kim, Y. H.
    Seol, Y. M.
    Mwatha, T.
    Grim, J.
    Ajani, J. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1044 - S1045
  • [45] Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).
    Ozaki, Yukinori
    Matsumoto, Koji
    Takahashi, Masato
    Mukohara, Toru
    Futamura, Manabu
    Masuda, Norikazu
    Tsurutani, Junji
    Yoshimura, Kenichi
    Minami, Hironobu
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [47] Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO
    Lorenzen, S.
    Pauligk, C.
    Goetze, T. O.
    Knorrenschild, J. Riera
    Goekkurt, E.
    Kullmann, F.
    Pink, D.
    Ettrich, T. J.
    Homann, N.
    Angermeier, S.
    Thuss-Patience, P. C.
    Lindig, U.
    Bitzer, M.
    Dechow, T.
    Schuch, G.
    Schmalenberg, H.
    Junge, S.
    Hofheinz, R. D.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III
    Robertson, Jane D.
    Botwood, Nick A.
    Rothenberg, Mace L.
    Schmoll, Hans-Joachim
    CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 59 - 60
  • [49] First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
    Liu, Tianshu
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Ruihua
    Guo, Weijian
    Qin, Shukui
    Yang, Nong
    Lu, Jianwei
    Shitara, Kohei
    Lei, Ming
    Li, Mingshun
    Bao, Nicole
    Chen, Tian
    Shen, Lin
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (04) : 749 - 760
  • [50] Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial
    Tyagi, Preeta
    Grothey, Axel
    CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 261 - 264
12345